Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interactions and Safety After Co-administration of Ilaprazole and Aceclofenac in Healthy Adults

Next Previous
Trial Profile

A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interactions and Safety After Co-administration of Ilaprazole and Aceclofenac in Healthy Adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aceclofenac (Primary) ; Ilaprazole (Primary)
  • Indications Ankylosing spondylitis; Gastro-oesophageal reflux; Osteoarthritis; Peptic ulcer; Reflux oesophagitis; Rheumatic disorders; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Il-Yang Pharmaceutical

Most Recent Events

  • 26 Jun 2023 Status changed from recruiting to completed.
  • 27 Feb 2023 Planned End Date changed from 10 Apr 2023 to 30 Dec 2023.
  • 27 Feb 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top